NP's/Dr. P's strategy (as stated on Monday's CC) to focus on filling enrollment on the mildly to moderately ill patient trial, and not on filling the severely ill patient trial, is brilliant. This is especially true in light of the Remdesivir story on Wednesday, which had to do only with severely ill patients; NP and Dr. P must have expected that this Gilead data was coming. If Leronlimab can stay in its own lane up until our mild to moderate trial is filled and the results are submitted, then we too can soon experience the kind of hoopla that Gilead received on Wednesday.